Compare OVLY & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVLY | LYEL |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.4M | 320.1M |
| IPO Year | 2008 | 2021 |
| Metric | OVLY | LYEL |
|---|---|---|
| Price | $32.61 | $12.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | 29.0K | ★ 230.3K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8,712.13 |
| P/E Ratio | $50.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.41 | $9.28 |
| 52 Week High | $35.97 | $45.00 |
| Indicator | OVLY | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 41.53 |
| Support Level | $32.64 | $11.59 |
| Resistance Level | $34.05 | $14.14 |
| Average True Range (ATR) | 0.95 | 1.19 |
| MACD | -0.12 | -0.08 |
| Stochastic Oscillator | 45.33 | 4.25 |
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.